Search results
Results from the WOW.Com Content Network
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
The pharmaceuticals ETF's expense ratio -- its annual fee -- is a relatively low 0.35%. The fund is somewhat small, too, so if you're thinking of buying, beware of possible large spreads between ...
Former CEO of Pernix Therapeutics, John Sedor, filed a claim in bankruptcy court for the amount of $1,534,375. John Sedor willingly and knowingly misled employees and shareholders of the company while backdoor negotiating an exit plan for Highbridge Capital Management to inflate the stock price a week before the bankruptcy was declared.
From 1997 to 1999, Peizer was president of Hollis-Eden, a startup pharmaceutical company. [19] [5] [43] The New York Times covered the company and his involvement in it in an article entitled: "No Sales, but Watch the Stock Soar". [19] By 1998 the company still had no sales or earnings. [19]
Kadmon Corporation (originally Kadmon Pharmaceuticals) is a biopharmaceutical company based in New York City.It also has operations in Warrendale, PA and Brighton, MA.The company was founded in 2009 by Samuel D. Waksal, [2] [3] founder and former CEO of ImClone Systems, a company now fully merged into Eli Lilly.
Separately, the analyst highlights the increasing use of Regeneron Pharmaceutical Inc’s 2 mg Eylea biosimilars, which have taken share from the branded version despite the availability of Eylea HD.
Vyera Pharmaceuticals (formerly Turing Pharmaceuticals) is a pharmaceutical company incorporated in Zug, Switzerland, with offices in New York City. The company started to do business in the US as Vyera Pharmaceuticals in September 2017.